Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine

Vascular Health and Risk Management

Volumn 3, Issue 3, 2007, Pages 245-254

  Ulrich, Heather ^a   Snyder, Benjamin ^a   Garg, Satish K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Body mass index (BMI); Glycemic control; Glycosylated hemoglobin Alc (HbAlc); Insulin glulisine; Rapid acting insulin analogues; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SOMATOMEDIN C;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; EXERCISE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KETOACIDOSIS; LIFESTYLE MODIFICATION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MITOGENESIS; MORTALITY; NEPHROGENIC DIABETES INSIPIDUS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNITED STATES; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34547693525     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. [AACE] American Association of Clinical Endocrinologists, American College of Endocrinology. 2002. Medical guidelines for the management of diabetes menitus: The AACE system of intensive diabetes self-management - 2002 update. Endocr Pract, 8(Suppl 1):40-82.
2. [ADA] American Diabetes Association. 2006. Standards of medical care in diabetes -2006. Diabetes Care, 29(Suppl 1):S4-S42.
3. American Diabetes Association. 2005. National Diabetes Fact Sheet [online]. Accessed September 28, 2006. URL: http://www.cdc.gov/diabetes/ puba/pdf/ndfs_2005.pdf.
4. Anderson J, Brunelle RL, Koivista VA, et al. 1997. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes, 46:265-70.
5. Becker RH, Frick AD, Burger F, et al. 2005. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes, 113:292-7.
6. Becker RHA, Frick AD, Kapizita CK, et al. 2004. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]. Diabetes, 53(Suppl 2):A119.
7. Becker RHA, Frick A, Wessels D. 2003. Pharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P]. Diabetes, 52(Suppl 1):A110.
8. Berti L, Kellerer M, Bossenmaier B, et al. 1998. The long-acting human insulin analog HOE901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res, 30:123-29.
9. Brunelle RL, Llewelyn J, Anderson J, et al. 1998. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care, 21:1726-31.
10. Dailey G, Rosenstock J, Moses RG, et al. 2004. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care, 27:2363-8.
11. Danne T, Becker RH, Heise T, et al. 2005. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care, 28:2100-5.
12. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977-86.
13. Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403.
14. Dreyer M, Prager R, Robinson A, et al. 2005. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res, 37:702-7.
15. Frick A, Becker RHA, Wessels D, et al. 2003. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract no. 471 -P]. Diabetes, 52(Suppl 1):A:110.
16. Frick A, Burger F, Scholtz H, et al. 2004. Time-action profile of insulin glulisine versus regular human insulin and insulin lispro in obese subjects [abstract no. 526-P]. Diabetes, 52(Suppl 2):A124.
17. Gabry KE. 2006. Application number: 21-629 (insulin glulisine). Medical Review [online] Accessed September 9, 2006. URL: www.fda.gov/cder/foi/nda/2004/21-629 Apidra Medr P1. pdf.
18. Garg S, Anderson J, Perry S, et al. 1999. Long-term efficacy of humalog in subjects with type 1 diabetes mellitus. Diabet Med, 16:384-87.
19. Garg SK, Ellis SL, Ulrich H. 2005. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother, 6:643-51.
20. Garg S. 2006. Safety, accuracy, and improvement in glucose profiles observed using a 7-day continuous glucose sensor. Diabetes Care, 29:2644-9.
21. Garg S, Rosenstock J, Ways K. 2005. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract, 11:11-7.
22. Garg S, Ulrich H. 2006. Achieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: practical strategies for success with insulin therapy. Insulin, 1:109-21.
23. Hirsch IB. 2004. Effect of insulin therapy on nonglycemic variables during acute illness. Endocr Pract, 10(Suppl 2):63-70.
24. Home PD, Lindholm A, Hylleberg B, et al. 1998. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care, 21:1904-09.
25. Hoogma RP, Schumicki D. 2006. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res, 38:429-33.
26. Howey DC, Bowsher RR, Brunelle RL, et al. 1994. [Lys(B28),Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes, 43:396-402.
27. [IDF] International Diabetes Federation. 1999. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med, 16:716-30.
28. [IDF] International Diabetes Federation. 2006. Executive Summary of the Diabetes Atlas, second addition [online]. Accessed September 28, 2006. URL: http://www.eatlas.idf.org/.
29. Jaros M, Martinek V, Piechatzek R, et al. 2004. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients [abstract no. 1330-P]. Diabetes, 53(Suppl 2):A321-22.
30. Monnier L, Lapinski H, Colette C. 2003. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1 c). Diabetes Care, 26:881-5.
31. Nathan DM, Cleary PA, Backlund JY. 2005. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes. N Engl J Med, 353:2643-53.
32. Nosek L, Becker RHA, Frick AD, et al. 2004. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract no.588-P]. Diabetes, 53 (Suppl 2):A139-40.
33. Overmann H, Heinemann L. 1999. Inection-meal interval: recommendations of diabetologists and how patients handle it. Diab Res Clin Pract, 43:137-42.
34. Plank J, Siebenhofer A, Berghold A, et al. 2005. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med, 165:1337-44.
35. Polonsky KS, Sturis J, Bell G. 1996. Non-insulin dependent diabetes mellitus: a genitically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med, 334:777-83.
36. Rave K, Nosek L, Heinemann L, et al. 2004. Insulin glulisine: pharmacokinetic and pharmacodynamic properties in comparison with insulin lispro and regular human insulin in Japanese and caucasian volunteers [abstract no. 603-P]. Diabetes, 53(Suppl 2):A143.
37. Rossetti L, Giaccari A, DeFronzo RA. 1990. Glucose toxicity. Diabetes Care, 13:610-30.
38. Shichiri M, Kishikawa H, Ohkubo Y, et al. 2000. Long term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23(Suppl 2):B21-9.
39. Sobel BE, Frye R, Detre KM. 2003. Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Trial Circulation, 107:636-42.
40. Spitzer H, Heise T, Heinemann L, et al. 2006. Insulin glulisine: faster onset of absorption and action than insulin lispro in lean to obese subjects [abstract no. 0148]. Diabetologia, 49(Suppl 1):94-5.
41. Stammberger I, Seipke G, Bartels T. 2006. Insulin glulisine-a comprehensive preclinical evaluation. Int J Toxicol, 25:25-33.
42. Stratton IM, Adler AI, Neil HAW, et al; on behalf of the UK Prospective Diabetes Study Group. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321:405-12.
43. Turner RC, Cull CA, Frighi V, et al; for the UK Prospective Diabetes Study (UKPDS) Group. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 281:2005-12.
44. [UKPDS] UK Prospective Diabetes Study Group. 1998. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53).
45. [UKPDS] UK Prospective Diabetes Study Group. 1995. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes, 44:1249-58.
46. Wittlin SD, Woehrle HJ, Gerich JE. 2002. Insulin pharmacokinetics. In Insulin Therapy. New York, NY: Marcel Dekker Inc.
47. World Health Organization. 2006. Diabetes action now [online]. Accessed September 9, 2006. URL: www.who.int/diabetes/actionnow/en/DANbooklet.pdf.